Meghan Joyce
About Meghan V. Joyce
Meghan V. Joyce (age 40) is an independent Class A director of The Boston Beer Company (SAM), serving since 2019; she is Chair of the Nominating/Governance Committee and a member of the Audit Committee . She is Co‑Founder and CEO of Duckbill Technologies (since Apr 2022), previously COO and EVP of Platform at Oscar Health (2019–Apr 2022; now Senior Advisor), and earlier held senior roles at Uber, served as a Senior Policy Advisor at the U.S. Treasury, and worked at Bain Capital and Bain & Company . She is recognized by SAM as an “audit committee financial expert” under SEC rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Oscar Health (NYSE: OSCR) | COO and EVP of Platform | Sep 2019 – Apr 2022 (Senior Advisor since Apr 2022) | Oversaw operations, technology, marketing, clinical operations, and tech/services solutions |
| Uber Technologies | Regional GM, U.S. & Canada Cities; East Coast GM; Boston GM | 2013 – 2019 | Responsible for business outcomes and rider/driver experience |
| U.S. Department of the Treasury | Senior Policy Advisor | 2011 – 2012 | Policy advisory work in Washington, D.C. |
| Bain Capital | Investor | N/A | Investment experience |
| Bain & Company | Consultant | N/A | Strategy/consulting background |
External Roles
| Organization | Role | Committees |
|---|---|---|
| Guardant Health, Inc. (NASDAQ: GH) | Director (appointed Aug 2021) | Audit Committee; Compensation Committee |
Board Governance
- Independence and roles: Joyce is an independent director; only independent directors may serve on SAM’s Audit, Compensation, and Nominating/Governance Committees . Current SAM roles: Nominating/Governance Committee (Chair) and Audit Committee .
- Audit Committee financial expertise: SAM’s Board determined all four current Audit Committee members, including Joyce, are “audit committee financial experts” (SEC definition) .
- Attendance and engagement: The Board held 5 regular meetings in FY2024; each director attended at least 75% of Board and committee meetings, and all directors attended the 2024 annual meeting . The Audit Committee held 4 regular meetings in 2024; the Nominating/Governance Committee held 4 regular meetings in 2024 .
- Executive sessions and leadership: Independent directors met in executive session four times during FY2024; the Lead Director (Julio Nemeth) leads these sessions .
- Committee evolution: With the announced retirement of director Jean‑Michel Valette in May 2025, committee and chair assignments will be reset at the May 2025 meetings (affects Audit Chair vacancy) .
- Governance policy enhancements: In 2024, SAM added a formal Chairman succession protocol (recommended by Nom/Gov) and updated Corporate Governance Guidelines, including an overboarding policy .
Fixed Compensation (Non-Employee Director – FY2024)
| Component | 2024 Amount ($) | Notes |
|---|---|---|
| Cash retainer + committee retainers | 105,000 | SAM’s schedule: $75,000 base retainer; $20,000 committee chair; $10,000 per committee membership (non-chair). Joyce’s mix aligns with Nom/Gov Chair (+$20k) and Audit member (+$10k) . |
| Option awards (grant-date fair value) | 65,173 | Annual non-employee director option award per schedule (~$65k) . Options fully vested at grant under Director Equity Plan . |
| RSU awards (grant-date fair value) | 65,017 | Annual RSU award per schedule (~$65k) . RSUs vest one year from grant, contingent on continued service . |
| Total | 235,190 | — |
- Director compensation schedule (adopted Feb 2023): Annual cash retainer $75,000; committee chair $20,000; committee member $10,000; Lead Director $20,000; annual equity: options ($65k) and RSUs ($65k); one‑time option and RSU awards (~$65k each) upon first-time election or appointment .
- FY2024 grants: On May 7, 2024, each non-employee director elected at that time (including Joyce) received options to purchase 568 Class A shares at a $268.20 exercise price; options are fully vested at grant; RSU grants of 243 units vest in one year .
Performance Compensation
- Performance linkage to director pay: None disclosed. Director RSUs are time-based (one-year vest), and options vest immediately; there are no performance metrics tied to director equity awards under the Director Equity Plan .
- Executive plan context (for comparison only): Company uses Depletions Growth, Net Revenue Growth (CAGR), EBIT (adjusted), and Focused Cost Savings for executive incentive programs; these do not apply to director compensation .
Other Directorships & Interlocks
| Company | Type | Committee Roles | Potential Interlock/Conflict with SAM |
|---|---|---|---|
| Guardant Health, Inc. | Public company board | Audit; Compensation | No SAM-related transactions disclosed; no related-party concerns noted for Joyce |
Expertise & Qualifications
- Skills cited by SAM as relevant: Business strategy, managing growth, financial modeling, modern consumer recruitment/engagement, digital marketing/technology implementation, and managing/retaining diverse employee groups .
- Governance credentials: Chair of Nominating/Governance since May 2020; Audit Committee member since 2019; prior service on Compensation Committee (2019–2020) . Recognized as an “audit committee financial expert” .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (Class A) | 4,932 shares; represents less than 1% of outstanding Class A shares . |
| Components (per footnote) | Includes options to acquire 4,485 Class A shares (currently exercisable/within 60 days) and 243 unvested RSUs . |
| Unexercised option shares (aggregate) | 4,485 option shares held at FY2024 year-end (director-level table) . |
| 2024 equity grants | 243 RSUs (vest in 1 year) and 568 options at $268.20 exercise price; options fully vested at grant . |
| Hedging/pledging | Prohibited for directors; annual certification; company reports no known violations since policy adoption . |
| Ownership guidelines | Target Ownership = 4x annual base director cash fee; “shares” include beneficially owned shares and unvested RSUs, but exclude unexercised options; as of Feb 2025, 4 directors met the target and 6 had not (no director-specific status disclosed) . |
Governance Assessment
- Board effectiveness and engagement: Joyce holds two high‑leverage governance roles (Nom/Gov Chair; Audit member) and is designated an Audit Committee financial expert—positive for oversight of risk, audit, and governance frameworks . Attendance thresholds were met, and committee work was active (Audit and Nom/Gov each met four times in 2024) .
- Independence and conflicts: She is expressly independent; only independent directors serve on committees . SAM reports no related‑party transactions since Jan 1, 2024 other than specified Dogfish‑related items (none involving Joyce) .
- Incentive alignment: Director equity is split between immediately‑vested options ($65k grant-date value) and one‑year RSUs ($65k), plus cash fees (her 2024 cash = $105k); approximate mix ~45% cash / ~55% equity, using grant-date values . Ownership guidelines (4x cash fee; unvested RSUs count; options excluded) promote alignment, though individual compliance status is not disclosed .
- Policy safeguards: Strong prohibitions against hedging/pledging and an updated overboarding policy enhance investor protections; no known policy violations .
- RED FLAGS: None disclosed specific to Joyce (no related‑party transactions, no attendance shortfall, no hedging/pledging, and committees limited to independent directors) .
Appendix: Reference Tables
Director Compensation (FY2024)
| Metric | Amount ($) |
|---|---|
| Fees Paid in Cash | 105,000 |
| Option Awards (grant‑date fair value) | 65,173 |
| RSU Awards (grant‑date fair value) | 65,017 |
| Total | 235,190 |
Director Equity Detail (FY2024 actions and holdings)
| Item | Detail |
|---|---|
| Option grant (annual) | 568 shares at $268.20 exercise price on May 7, 2024; fully vested at grant . |
| RSU grant (annual) | 243 RSUs on May 7, 2024; vests one year from grant contingent on service . |
| Unexercised option shares held (aggregate) | 4,485 shares . |
Beneficial Ownership (as of record date in 2025 proxy)
| Holder | Shares Beneficially Owned | Percent of Class |
|---|---|---|
| Meghan V. Joyce | 4,932 | <1% |
Committee Assignments (as of 2025 proxy mailing)
| Committee | Role |
|---|---|
| Nominating/Governance | Chair |
| Audit | Member; designated “audit committee financial expert” |
Policy Highlights
- Insider Trading Policy: Prohibits hedging/pledging; annual certification; no known violations .
- Director Ownership Guidelines: Target = 4x annual base director fee; counts unvested RSUs; excludes unexercised options; 4 directors at/above target; 6 below (no individual disclosure) .